NZ332995A - A protein which binds to osteoclastogenesis inhibitory factor (OCIF) - Google Patents

A protein which binds to osteoclastogenesis inhibitory factor (OCIF)

Info

Publication number
NZ332995A
NZ332995A NZ332995A NZ33299598A NZ332995A NZ 332995 A NZ332995 A NZ 332995A NZ 332995 A NZ332995 A NZ 332995A NZ 33299598 A NZ33299598 A NZ 33299598A NZ 332995 A NZ332995 A NZ 332995A
Authority
NZ
New Zealand
Prior art keywords
ocif
protein
binds
inhibitory factor
osteoclastogenesis inhibitory
Prior art date
Application number
NZ332995A
Inventor
Kyoji Yamaguchi
Hisataka Yasuda
Nobuaki Nakagawa
Nobuyuki Shima
Masahiko Kinosaki
Eisuke Tsuda
Masaaki Goto
Kazuki Yano
Akihiro Tomoyasu
Fumie Kobayashi
Naohiro Washida
Ken Takahashi
Tomonori Morinaga
Kanji Higashio
Original Assignee
Snow Brand Milk Products Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27525882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ332995(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Snow Brand Milk Products Co Ltd filed Critical Snow Brand Milk Products Co Ltd
Publication of NZ332995A publication Critical patent/NZ332995A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)

Abstract

The protein OBM (OCIF-binding molecule) binds to osteoclastogenesis inhibitory factor (OCIF) and exhibits high affinity to OCIF. This protein has a molecular weight of 30,000-40,000 Da and an apparent weight of 90,000-110,000 when crossed linked to a monomer type OCIF. The protein exhibits activity supporting or promoting osteoclast differentiation and maturation in a co-culture system of the osteoblastic stromal cells and spleen cells in the presence bone resorption stimulating factors. A pharmaceutical composition for the treatment of bone metabolism disorders is also described.
NZ332995A 1997-04-15 1998-04-15 A protein which binds to osteoclastogenesis inhibitory factor (OCIF) NZ332995A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP9780897 1997-04-15
JP15143497 1997-06-09
JP21789797 1997-08-12
JP22480397 1997-08-21
JP33224197 1997-12-02
PCT/JP1998/001728 WO1998046644A1 (en) 1997-04-15 1998-04-15 Novel protein and process for producing the same

Publications (1)

Publication Number Publication Date
NZ332995A true NZ332995A (en) 2000-07-28

Family

ID=27525882

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ332995A NZ332995A (en) 1997-04-15 1998-04-15 A protein which binds to osteoclastogenesis inhibitory factor (OCIF)

Country Status (21)

Country Link
US (7) US7527790B2 (en)
EP (3) EP2336168A1 (en)
JP (7) JP3523650B2 (en)
KR (1) KR100496063B1 (en)
CN (1) CN1138786C (en)
AT (1) ATE328006T1 (en)
AU (1) AU735355B2 (en)
CA (2) CA2257247C (en)
CY (1) CY2010017I2 (en)
DE (2) DE122010000049I1 (en)
DK (1) DK0911342T4 (en)
ES (1) ES2263204T5 (en)
FR (1) FR10C0048I2 (en)
HU (3) HU229476B1 (en)
IL (1) IL127115A (en)
LU (1) LU91759I2 (en)
NO (2) NO322632B1 (en)
NZ (1) NZ332995A (en)
PT (1) PT911342E (en)
RU (1) RU2238949C2 (en)
WO (1) WO1998046644A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
WO1998025958A2 (en) * 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
EP2336168A1 (en) * 1997-04-15 2011-06-22 Sankyo Company Limited Novel protein and method for producing the protein
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
ATE363533T1 (en) 1997-04-16 2007-06-15 Amgen Inc OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
ATE412746T1 (en) * 1998-05-14 2008-11-15 Immunex Corp METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTS
TR200101146T2 (en) 1998-10-28 2001-09-21 Sankyo Co., Ltd. The substance that treats bone-pathobolism.
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
DE60134459D1 (en) † 2000-02-23 2008-07-31 Amgen Inc ANTAGONISTIC SELECTIVE BINDING AGENTS OF THE OSTEOPROTEGERIN BINDING PROTEIN
WO2002024896A2 (en) 2000-09-22 2002-03-28 Immunex Corporation Screening assays for agonists or antagonists of receptor activat or of nf-kb
WO2002062990A1 (en) * 2001-02-07 2002-08-15 Sankyo Company, Limited Antibody and utilization thereof
WO2002079256A1 (en) * 2001-03-26 2002-10-10 Sankyo Company, Limited Antibody and utilization thereof
ES2337716T3 (en) 2001-04-03 2010-04-28 Societe Des Produits Nestle S.A. OSTEOPROTEGERIN IN MILK.
MY143582A (en) 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
MXPA05006147A (en) * 2002-12-10 2005-08-26 Schering Plough Ltd Canine rankl and methods for preparing and using the same.
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
CA2535156A1 (en) 2003-08-08 2005-02-24 Abgenix, Inc. Antibodies directed to parathyroid hormone (pth) and uses thereof
US7318925B2 (en) 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
AR045563A1 (en) * 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
DK2311873T3 (en) 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
RU2324425C2 (en) * 2005-08-30 2008-05-20 Государственное образовательное учреждение "Институт усовершенствования врачей" Министерства здравоохранения и социального развития Method for preventing birth of infants with ostepetrosis
PE20070684A1 (en) 2005-11-14 2007-08-06 Amgen Inc RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES
CA2640508C (en) * 2006-02-13 2014-04-15 Olga Ornatsky Gene expression assays conducted by elemental analysis
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
JP5210156B2 (en) 2006-05-12 2013-06-12 学校法人慶應義塾 Composition for detection of inflammatory diseases and prevention or treatment of inflammatory diseases
WO2008044379A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Bone loss model animal
WO2008044797A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Osteopenia model animal
CA2666415C (en) 2006-10-11 2012-11-27 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
JP5191487B2 (en) 2007-06-05 2013-05-08 オリエンタル酵母工業株式会社 New bone mass increasing drug
PL2206727T3 (en) 2007-10-11 2015-08-31 Daiichi Sankyo Co Ltd ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
WO2010053610A2 (en) * 2008-07-30 2010-05-14 Emergent Biosolutions, Inc. Stable anthrax vaccine formulations
US9435811B2 (en) 2008-09-30 2016-09-06 Oriental Yeast Co., Ltd Inducer of chondrocyte proliferation and differentiation
JP2012520098A (en) * 2009-03-30 2012-09-06 エフ．ホフマン−ラ ロシュ アーゲー How to prevent fogging of glass
KR101690340B1 (en) * 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 ANTI-Siglec-15 ANTIBODY
WO2011017294A1 (en) * 2009-08-07 2011-02-10 Schering Corporation Human anti-rankl antibodies
EP2433644A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer therapeutics
EP2434285A1 (en) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Breast cancer diagnostics
KR20130066682A (en) 2010-10-05 2013-06-20 다이이찌 산쿄 가부시키가이샤 Antibody targeting osteoclast-related protein siglec-15
US20130280260A1 (en) * 2010-10-13 2013-10-24 Tokyo Women's Medical University Osteoclastogenesis inhibitor containing anti-vdac antibody
EP2692359B1 (en) 2011-03-31 2017-06-07 Oriental Yeast Co., Ltd. Cancer immunopotienting agent containing rankl antagonist
US10420801B2 (en) 2012-03-21 2019-09-24 The General Hospital Corporation Isolation and use of human lymphoid organ-derived suppressive stromal cells
US9464133B2 (en) 2012-03-30 2016-10-11 Daiichi Sankyo Company, Limited CDR-modified anti-Siglec-15 antibody
ES2723885T3 (en) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anti-Siglec-15 antibodies
CA2920376A1 (en) 2013-08-07 2015-02-12 Martin Blomberg JENSEN Methods and composition comprising denosumab or an antibody or antigen binding domain, fragment or derivative thereof, immunoreactive with a rankl/opgbp peptide for use in the treatment, prevention or alleviation of male infertility
WO2015100344A1 (en) 2013-12-27 2015-07-02 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
AU2016422911B2 (en) * 2016-09-13 2021-04-01 E&S Healthcare Co., Ltd. Monoclonal antibody specifically binding to thioredoxin 1, and use thereof
CN108410990B (en) * 2018-05-30 2021-07-06 中国医学科学院北京协和医院 Application of IGFBP3 in the preparation of products for the diagnosis of type I neurofibromas complicated with spinal deformity
CN111205354B (en) * 2020-01-22 2021-01-22 天津科技大学 A kind of signal peptide mutant that improves the secretion amount of heterologous protein and its construction method and use
CN111333709B (en) * 2020-03-17 2023-09-08 吉林大学 Trichinella spiralis muscle larval stage serine protease inhibitor B cell epitope peptides, hybridoma cell lines, monoclonal antibodies and applications

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
WO1986000922A1 (en) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Retroviral gene transfer vectors
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
JP2877509B2 (en) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド Metalloproteinase inhibitors
CA2071912C (en) * 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (en) 1991-05-13 1992-11-14 Masahiko Sato Method for inhibiting bone resorption
MX9204303A (en) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int REGULATORY FACTOR OF OSTEOCLAST GROWTH.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int Transgenic non-human animals capable of producing heterologous antibodies
US5623053A (en) * 1992-01-10 1997-04-22 California Institute Of Technology Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH07509223A (en) 1992-04-30 1995-10-12 アムジェン インコーポレイテッド Methods for treating interleukin-1-mediated and tumor necrosis factor-mediated diseases
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (en) 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド CDNA encoding a novel human protein tyrosine phosphatase
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
EP0727211A1 (en) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Use of src SH2 specific compounds to treat a bone resorption disease
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1996028546A1 (en) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
WO1997000317A1 (en) 1995-06-07 1997-01-03 Osteosa Inc. Osteoclast growth regulatory factor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US5662948A (en) * 1996-01-29 1997-09-02 Chrysler Corporation Adjustable and removable trimline inserts for a molding tool
US6750091B1 (en) * 1996-03-01 2004-06-15 Micron Technology Diode formation method
JPH1057071A (en) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd Novel DNA and method for producing protein using the same
WO1998025958A2 (en) * 1996-12-13 1998-06-18 Schering Corporation Mammalian cell surface antigens comprising structural motifs characteristic of a member of the tnf ligand family
FR2757507B1 (en) 1996-12-20 1999-01-29 Inst Francais Du Petrole PARAXYLENE SEPARATION PROCESS COMPRISING ADSORPTION WITH WATER INJECTION AND CRYSTALLIZATION
WO1998028423A2 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
EP2003203A1 (en) * 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2336168A1 (en) * 1997-04-15 2011-06-22 Sankyo Company Limited Novel protein and method for producing the protein
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
ATE363533T1 (en) 1997-04-16 2007-06-15 Amgen Inc OSTEOPROTEGERIN BINDING PROTEINS AND RECEPTORS
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
JP2002514079A (en) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド Chimeric OPG polypeptide
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
ATE412746T1 (en) 1998-05-14 2008-11-15 Immunex Corp METHOD FOR INHIBITING THE EFFECT OF OSTEOCLASTS
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
CA2349406C (en) 1999-09-03 2011-01-11 Amgen Inc. Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
MY143582A (en) * 2001-06-26 2011-05-31 Amgent Fremont Inc Antibodies to opgl
PL375041A1 (en) * 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors

Also Published As

Publication number Publication date
US20100136011A1 (en) 2010-06-03
JP2013139465A (en) 2013-07-18
JP5285751B2 (en) 2013-09-11
NO985848D0 (en) 1998-12-14
FR10C0048I2 (en) 2013-08-16
JP4230993B2 (en) 2009-02-25
WO1998046644A1 (en) 1998-10-22
JP4878616B2 (en) 2012-02-15
US7449185B2 (en) 2008-11-11
CA2257247A1 (en) 1998-10-22
AU6851898A (en) 1998-11-11
US20030176647A1 (en) 2003-09-18
FR10C0048I1 (en) 2011-01-14
US20080187540A9 (en) 2008-08-07
EP1657255A1 (en) 2006-05-17
KR100496063B1 (en) 2005-06-21
EP2336168A1 (en) 2011-06-22
JP4355357B2 (en) 2009-10-28
RU2238949C2 (en) 2004-10-27
ES2263204T3 (en) 2006-12-01
PT911342E (en) 2006-08-31
AU735355B2 (en) 2001-07-05
LU91759I2 (en) 2011-01-24
DE69834699T3 (en) 2013-11-14
US20120329671A1 (en) 2012-12-27
DE69834699T2 (en) 2007-05-16
US20050003457A1 (en) 2005-01-06
EP1657255B1 (en) 2014-07-30
ATE328006T1 (en) 2006-06-15
NO2010021I1 (en) 2011-01-10
DE122010000049I1 (en) 2011-05-05
US20050208580A1 (en) 2005-09-22
DK0911342T3 (en) 2006-08-21
LU91759I9 (en) 2019-01-02
DK0911342T4 (en) 2013-07-29
US7527790B2 (en) 2009-05-05
HU229841B1 (en) 2014-09-29
HUS1400027I1 (en) 2016-10-28
CY2010017I2 (en) 2012-01-25
NO2010021I2 (en) 2015-03-09
JP2009013177A (en) 2009-01-22
US20070009520A1 (en) 2007-01-11
JP3523650B2 (en) 2004-04-26
CA2257247C (en) 2012-09-11
NO322632B1 (en) 2006-11-06
DE69834699D1 (en) 2006-07-06
EP0911342A1 (en) 1999-04-28
HU229476B1 (en) 2014-01-28
CA2781623A1 (en) 1998-10-22
ES2263204T5 (en) 2013-10-14
JP3935861B2 (en) 2007-06-27
NO985848L (en) 1999-02-15
US7192718B2 (en) 2007-03-20
CY2010017I1 (en) 2011-02-02
IL127115A (en) 2013-08-29
IL127115A0 (en) 1999-09-22
JP2009029834A (en) 2009-02-12
JP2005176847A (en) 2005-07-07
AU735355C (en) 1998-11-11
JP2004041195A (en) 2004-02-12
JP2012041345A (en) 2012-03-01
CN1222917A (en) 1999-07-14
CN1138786C (en) 2004-02-18
JP5593407B2 (en) 2014-09-24
HU0800628D0 (en) 2010-06-28
EP0911342A4 (en) 2002-11-27
EP0911342B2 (en) 2013-05-22
EP0911342B1 (en) 2006-05-31
HUP0000717A2 (en) 2000-06-28
KR20040004509A (en) 2004-01-13
US20030208045A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
NZ332995A (en) A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
ATE259828T1 (en) PROSAPOSIN AND CYTOKINE-DEPENDENT PEPTIDES AS THERAPEUTIC AGENTS
IE891542L (en) Peptides having t cell helper activity
GEP20012444B (en) 6-Aryl Pyrido[2,3-d]Pyrimidines and Naphthyridines, Pharmaceutical Composition on Their Basis and Application for Inhibiting Cellular Proliferation
AU3368497A (en) Human dnase i hyperactive variants
AU1877495A (en) Naphthylamides as central nervous system agents
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
FR2738151B1 (en) ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
UA52594C2 (en) Cycloalcanopyridine derivatives, mixture of isomers thereof or individual isomers, their salts and n-oxides, methods and intermediate compounds for preparation thereof, a also a pharmaceutical composition
AU8377698A (en) Inhibitors of p38
CA2274825A1 (en) Substituted nitrogen containing heterocycles as inhibitors of p38 protein kinase
ZA943464B (en) Vascular endothelial growth factor 2
YU34196A (en) Peptides and compounds that bind to a receptor
Ichinose et al. Tumor necrosis factor and IL-1 associated with plasma membranes of activated human monocytes lyse monokine-sensitive but not monokine-resistant tumor cells whereas viable activated monocytes lyse both.
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
WO1995019570B1 (en) Antagonists to insulin receptor tyrosine kinase inhibitor
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
ATE195124T1 (en) CONDENSED PYRROLO(2,3-C) CARBAZOLE-6-ONE WHICH POTENTIATE THE ACTIVITY OF GAMMA INTERFERON
EP1702929A3 (en) Therapeutic use of the smr1 protein and active derivatives thereof
CA2388910A1 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
MX9403088A (en) Indole derivatives.
BR0304963A (en) Compounds, pharmaceutical composition, and, methods for modulating adenosine activity in a mammal, and for treating a mammal suffering from or susceptible to diseases.
CA2094275A1 (en) Methods and compositions for the treatment of cell proliferation disorders
WO1991003226A3 (en) Pharmaceutical compositions containing aromatic polymers and therapeutic methods using the same
GB9711389D0 (en) Bacterial pheromones and uses therefor

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired